Healthcare
Live Price
Offline$113.13
+0.00% today
1Y Change
+0.00%
Window
Jun 30, 2025 → Jun 26, 2026
Coverage: 255 bars · Jun 30, 2025 → Jun 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ipsen S.A. (IPSEF) is a Healthcare stock with a market cap of $13.81B and listed on OTC. The stock last traded around $113.13 and up 0.0% across the available one-year price window (Jun 30, 2025 → Jun 26, 2026). Baseline metrics include revenue growth of +2.8%, EPS growth of +23.1%, a dividend yield of 0.8%. What stands out right now is revenue +2.8%, EPS +23.1%, free cash flow +676.5% with operating margin 30.7% and ROIC 15.4%. The dividend is present but secondary, with a yield around 0.8%. Valuation already assumes a fairly strong business story at P/E 31.0 and price/sales 3.8. Stock Foundry combines IPSEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
IPSEF is 17.99 pts behind over the shared 1Y window.
IPSEF had 9.13 pts shallower max drawdown than SPY.
IPSEF beat SPY in 0 of 2 calendar years shown and trailed in 2.
IPSEF
+0.00%
Normalized return
SPY
+17.99%
S&P 500
Excess Return
-17.99 pts
Relative to SPY
IPSEF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for IPSEF and SPY.
| Year | IPSEF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | 0.00% | +6.71% | -6.71 pts | SPY |
| 2025 | 0.00% | +11.19% | -11.19 pts | SPY |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.0B
-5.0% YoY
FY Net Income
$646.6M
-0.3% YoY
Free Cash Flow
$481.5M
-33.0% YoY
Revenue Growth
+2.8%
EPS Growth
+23.1%
Gross Margin
70.6%
Net Margin
12.1%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.7B | 3.6B | 3.3B | 3.2B | 3.0B |
| Gross Profit | 2.6B | 3.0B | 2.7B | 2.6B | 2.5B |
| Operating Income | 746M | 497M | 816M | 730M | 850M |
| EBITDA | 1.1B | 1.2B | 887M | 938M | 1.1B |
| Net Income | 444M | 346M | 644M | 649M | 647M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.5B | 678M | 528M | 1.2B | 815M |
| Total Assets | 6.9B | 6.4B | 6.3B | 5.6B | 5.0B |
| Total Liabilities | 2.6B | 2.3B | 2.5B | 2.3B | 2.3B |
| Shareholder Equity | 4.3B | 4.2B | 3.8B | 3.3B | 2.8B |
| Total Debt | 1.1B | 427M | 306M | 4M | 693M |
| Net Debt | -471M | -251M | -222M | -1.2B | -122M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
909M
-6.4% YoY
Capital Expenditures
428M
-69.1% YoY
Free Cash Flow
482M
-33.0% YoY
Key ratios
Gross Margin
70.6%
Operating Margin
30.7%
Net Margin
12.1%
ROE
10.4%
Debt / Equity
0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.